• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP-ACIP vote on combo measles vaccine could especially affect families in greater need

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/anti-sci...could-especially-affect-families-greater-need

ACIP vote on combo measles vaccine could especially affect families in greater need



Laine Bergeson


Today at 4:59 p.m.

Anti-science

Childhood Vaccines

Measles

Mumps

Rubella

Varicella
Children receiving a combination measles, mumps, rubella, and varicella vaccine (MMRV) may be more likely to come from low-income and underserved communities, according to a new study published in JAMA Network Open.

The findings come less than a year after a Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) vote to remove the MMRV vaccine as a recommended option for children under the age of four years. The vote also excluded it from coverage by Vaccines for Children (VFC), a federal program that provides vaccines to kids whose parents may not be able to afford them.

The vaccine covers not only measles and mumps, but "German measles" (rubella) and chickenpox (varicella), as well.

Combination vaccines may help improve coverage


The study examined how more than 213,000 children in King County, Washington, received their first measles- and varicella-containing vaccines from 2015 to 2025. Researchers, primarily from Public Health–Seattle & King County, found that children who received the MMRV vaccine were more likely to get care at safety-net clinics, belong to racial and ethnic minority groups, and qualify for enrollment in VFC.

Of the children in the study, 15% received the MMRV vaccine as their first dose and 64% received separate measles, mumps, and rubella (MMR) and varicella vaccines (VAR) during the same visit. Although those receiving the MMRV vaccine were in the minority, they were more likely to be Hispanic; American Indian or Alaska Native, Black, Native Hawaiian or Pacific Islander, or multiracial; eligible for VFC; vaccinated in safety-net clinics; and receiving catch-up vaccinations after the recommended age.

This population might be at risk of not receiving recommended vaccines if options become limited.

Combination vaccines reduce the number of injections, clinic visits, and costs required to complete a vaccine series, note the authors, and in clinics serving families with limited resources, that may help improve vaccine coverage. "This population might be at risk of not receiving recommended vaccines if options become limited," the researchers write. In an accompanying commentary, Elizabeth Cope, PhD, MPH, and Aaron Carroll, MD, agree: "Those benefits matter most to families with the least slack: hourly work, no paid sick leave, and a follow-up visit that may not happen."

ACIP recommendation made without equity considerations


When ACIP opted to remove the MMRV vaccine as a recommended option for young children in September 2025, the vote occurred without a population analysis, notes the commentary.

“It also came without an Evidence-to-Recommendations framework analysis,” or the “structured process ACIP has historically used to document how equity, feasibility, acceptability, patient values, and resource implications factor into any recommendation change,” Cope and Carroll write.

Transparency in the sense of public visibility remained intact; transparency in the sense of auditable, evidence-based deliberation did not.

Those weren’t the only procedural concerns. “Liaison organizations were excluded from deliberations,” continues the commentary, and the “MMRV vote itself required reconsideration after confusion among committee members about what had been voted on. Transparency in the sense of public visibility remained intact; transparency in the sense of auditable, evidence-based deliberation did not.”

In 2009, faced with MMRV safety data indicating a small but real increase in febrile seizure risk for children under age four, an earlier iteration of ACIP—before it was stacked with vaccine skeptics last year—voted to make receiving separate MMR and VAR vaccines during the same visit the default recommendation, but allowed for MMRV vaccination after provider-caregiver consultations. “That kind of compromise is what the patient-clinician conversation is for,” notes the commentary.

Seizure risk is genuine


The study comes with caveats. It was limited to a single county, so the findings may not apply nationwide. And the risk of febrile seizure is genuine.

“We are not arguing about the size of that risk,” write Copeland and Carroll. “We are arguing about the procedure that should have weighed the risks and about the stakeholders, including families, who were not in the room when it was weighed.”

For Copeland and Carroll, the findings highlight broader issues around how vaccine policy decisions are made. "Questions about who uses an intervention, who benefits from having a choice, and who is affected by reduced access are not peripheral to vaccine policy," Cope and Carroll wrote. "They are central to evidence-based vaccine policy."
 
Back
Top Bottom